HAOHAI BIOTEC (06826) announced on November 7, 2025, that its wholly-owned subsidiary, Shanghai HAOHAI Medical Technology, as the transferee, entered into a supplementary equity transfer agreement with the transferors, Mr. Zhang, Shenzhen Jiusi, and Shenzhen Baina. The transferors agreed to sell the remaining 20% stake in the target company, Shenzhen New Industries Ophthalmology New Technology Co., Ltd., to the transferee for RMB74 million. Upon completion of the acquisition, the group will hold a 100% stake in the target company.

The target company, incorporated in China, is primarily engaged in the manufacturing and sales of orthokeratology lenses and intraocular lens products, as well as the distribution of imported ophthalmic products in mainland China, including intraocular lenses, ophthalmic viscoelastic agents, and sodium hyaluronate gel for glaucoma surgery.

Since acquiring 60% and 20% stakes in the target company in November 2016 and February 2023, respectively, the group has been steadily expanding into the high-value ophthalmic consumables sector. After years of integration and development, the group has become a leading manufacturer of intraocular lens products in China, with the target company emerging as one of its key subsidiaries. The acquisition will increase the group's stake in the target company to 100%, enhancing management and operational efficiency while strengthening the market competitiveness of its ophthalmic products. The board believes the acquisition aligns with the group's development needs and overall business strategy.